JP2012517225A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012517225A5 JP2012517225A5 JP2011549110A JP2011549110A JP2012517225A5 JP 2012517225 A5 JP2012517225 A5 JP 2012517225A5 JP 2011549110 A JP2011549110 A JP 2011549110A JP 2011549110 A JP2011549110 A JP 2011549110A JP 2012517225 A5 JP2012517225 A5 JP 2012517225A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- sequence number
- bacteriophage
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 36
- 102000004169 proteins and genes Human genes 0.000 claims 36
- 241001515965 unidentified phage Species 0.000 claims 36
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 230000000845 anti-microbial effect Effects 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 18
- 150000007523 nucleic acids Chemical group 0.000 claims 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 230000000844 anti-bacterial effect Effects 0.000 claims 14
- 241000894006 Bacteria Species 0.000 claims 12
- 241000588626 Acinetobacter baumannii Species 0.000 claims 11
- 241000194032 Enterococcus faecalis Species 0.000 claims 11
- 229940032049 enterococcus faecalis Drugs 0.000 claims 11
- 241000191967 Staphylococcus aureus Species 0.000 claims 10
- 241000194031 Enterococcus faecium Species 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 9
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 8
- 239000013543 active substance Substances 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 101000870242 Bacillus phage Nf Tail knob protein gp9 Proteins 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 101710204224 Tape measure protein Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 241000194033 Enterococcus Species 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 206010011409 Cross infection Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 230000005757 colony formation Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000676 disease causative agent Toxicity 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15058509P | 2009-02-06 | 2009-02-06 | |
| US61/150,585 | 2009-02-06 | ||
| US21834509P | 2009-06-18 | 2009-06-18 | |
| US61/218,345 | 2009-06-18 | ||
| PCT/PT2010/000003 WO2010090542A2 (en) | 2009-02-06 | 2010-02-05 | Antibacterial phage, phage peptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015029248A Division JP6177264B2 (ja) | 2009-02-06 | 2015-02-18 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012517225A JP2012517225A (ja) | 2012-08-02 |
| JP2012517225A5 true JP2012517225A5 (enExample) | 2013-05-02 |
| JP5701777B2 JP5701777B2 (ja) | 2015-04-15 |
Family
ID=42244489
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011549110A Active JP5701777B2 (ja) | 2009-02-06 | 2010-02-05 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
| JP2015029248A Active JP6177264B2 (ja) | 2009-02-06 | 2015-02-18 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
| JP2017083578A Active JP6355792B2 (ja) | 2009-02-06 | 2017-04-20 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015029248A Active JP6177264B2 (ja) | 2009-02-06 | 2015-02-18 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
| JP2017083578A Active JP6355792B2 (ja) | 2009-02-06 | 2017-04-20 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9134312B2 (enExample) |
| EP (3) | EP3115054B1 (enExample) |
| JP (3) | JP5701777B2 (enExample) |
| CN (2) | CN105456300B (enExample) |
| AU (1) | AU2010211456B2 (enExample) |
| BR (1) | BRPI1008663B8 (enExample) |
| CA (2) | CA2751641C (enExample) |
| ES (2) | ES2761835T3 (enExample) |
| PL (1) | PL3650034T3 (enExample) |
| PT (1) | PT3115054T (enExample) |
| RU (2) | RU2580248C9 (enExample) |
| SG (3) | SG10201602330VA (enExample) |
| WO (1) | WO2010090542A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0607798D0 (en) * | 2006-04-20 | 2006-05-31 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
| CA2729160C (en) * | 2008-07-03 | 2017-11-14 | The Rockefeller University | A chimeric bacteriophage lysin with activity against staphylococci bacteria |
| US8273564B2 (en) * | 2009-08-12 | 2012-09-25 | Tzu Chi Buddhist General Hospital | Disinfectant composition comprising phage of Acinetobacter baumannii |
| PT104837A (pt) | 2009-11-24 | 2011-05-24 | Technophage Investiga O E Desenvolvimento Em Biotecnologia S A | P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o |
| CA3154006C (en) | 2010-09-17 | 2025-09-09 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia S.A. | Antibacterial phages, phage peptides and their methods of use |
| KR101279780B1 (ko) | 2011-10-05 | 2013-06-28 | 주식회사 인트론바이오테크놀로지 | 액티노바실러스 플루로뉴모니애에 대한 사멸능을 갖는 박테리오파지 |
| JP6186427B2 (ja) * | 2012-03-19 | 2017-08-23 | テクニファー−インダストリア テクニカ ファーマシューティカ,エス.エー. | 抗菌性ファージのカクテルを含む組成物及び細菌感染症を処置するためのその使用 |
| JP6250639B2 (ja) * | 2012-05-04 | 2017-12-20 | バイオコントロール リミテッドBiocontrol Limited | 治療用バクテリオファージ組成物 |
| EP2865383A1 (en) * | 2013-10-25 | 2015-04-29 | Pherecydes Pharma | Phage therapy of pseudomonas infections |
| US9029319B1 (en) * | 2014-08-04 | 2015-05-12 | Centaur, Inc. | Water buffalo derived peptide antibiotic therapies |
| WO2016098116A1 (en) * | 2014-12-17 | 2016-06-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Phage therapy for targeting enterococci |
| CN105294840B (zh) * | 2015-11-20 | 2018-08-17 | 深圳市南山区人民医院 | 一种用于预防和治疗肠致病大肠杆菌感染的肽段 |
| US20170157186A1 (en) * | 2015-12-02 | 2017-06-08 | Smart Phage, Inc. | Phage to treat bacteria on skin |
| CN105648109B (zh) * | 2016-01-08 | 2019-04-09 | 河南医学高等专科学校 | 一种噬菌体灭菌时化学抗菌剂筛选方法 |
| CN106699862B (zh) * | 2016-11-22 | 2020-06-09 | 中国科学院海洋研究所 | 三种来源于脊尾白虾alf的环状多肽及其应用和抗菌剂 |
| AU2017371484B2 (en) | 2016-12-05 | 2022-09-15 | Technophage, Investigação e Desenvolvimento Em Biotecnologia SA | Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof |
| CA3053332A1 (en) * | 2017-02-17 | 2018-08-23 | CAMRIS International, Inc. | Universal antivenom |
| KR101957266B1 (ko) * | 2017-02-22 | 2019-03-13 | 주식회사 인트론바이오테크놀로지 | 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2 |
| CN107365363B (zh) * | 2017-09-20 | 2020-08-04 | 苏州大学 | 小分子多肽及其应用 |
| CN107827955B (zh) * | 2017-11-21 | 2020-05-29 | 苏州大学 | 源于分枝杆菌噬菌体多肽的衍生肽及其应用 |
| KR20200098615A (ko) | 2017-12-12 | 2020-08-20 | 콘트라펙트 코포레이션 | 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체 |
| EP3766967B1 (en) * | 2018-03-12 | 2025-03-26 | National University Corporation Kochi University | Novel bacteriophage and treatment agent for bacterial endophthalmitis |
| WO2019224941A1 (ja) * | 2018-05-23 | 2019-11-28 | 国立大学法人九州大学 | 食中毒細菌のバクテリオファージ耐性化抑制剤及びその使用 |
| KR102131692B1 (ko) * | 2018-09-11 | 2020-07-08 | 경북대학교 산학협력단 | 병원성 세균을 효과적으로 사멸시키는 재조합 항균 효소 LysSAP26의 용도 |
| RU2703043C1 (ru) * | 2018-09-20 | 2019-10-15 | Наталия Петровна Антонова | Литический фермент бактериофага и антибактериальная композиция на его основе |
| KR102193495B1 (ko) * | 2018-12-26 | 2020-12-22 | 주식회사 옵티팜 | 신규한 아시네토박터 바우마니 균 특이 박테리오파지 ab63 및 이를 포함하는 항균 조성물 |
| EP3946609A4 (en) * | 2019-04-05 | 2023-05-03 | Contrafect Corporation | LYSINE AND ITS DERIVATIVES WITH BACTERICIDAL ACTIVITY AGAINST PSEUDOMONAS AERUGINOSA IN THE PRESENCE OF HUMAN SERUM |
| WO2020207884A1 (en) * | 2019-04-09 | 2020-10-15 | Unilever N.V. | An antimicrobial composition for selective lysis of s. hominis bacteria |
| US12396460B2 (en) * | 2019-06-17 | 2025-08-26 | Precisio Biotix Therapeutics, Inc. | Bacterial control through dispersion of bacteriophage powders |
| RU2717435C1 (ru) * | 2019-06-28 | 2020-03-23 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 326 (500320), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717451C1 (ru) * | 2019-06-28 | 2020-03-23 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717972C1 (ru) * | 2019-06-28 | 2020-03-27 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 324 (500318), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717026C1 (ru) * | 2019-06-28 | 2020-03-17 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 325 (500319), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717973C1 (ru) * | 2019-06-28 | 2020-03-27 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 322 (500316), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717022C1 (ru) * | 2019-06-28 | 2020-03-17 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 328 (500322), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717420C1 (ru) * | 2019-06-28 | 2020-03-23 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 327 (500321), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| CN110499266B (zh) * | 2019-08-05 | 2021-04-27 | 昆明理工大学 | 一株粪肠球菌及其应用 |
| US20210187046A1 (en) | 2019-12-19 | 2021-06-24 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof |
| CN113214364B (zh) * | 2020-01-21 | 2022-11-22 | 天津大学 | 一种多重耐药鲍曼不动杆菌识别元件的挖掘与验证 |
| US20230077209A1 (en) * | 2020-02-14 | 2023-03-09 | William Colton | Bacteriophage Cocktail-Containing Hydrogel Compositions and Methods of Production and Use Thereof |
| KR102604590B1 (ko) * | 2020-09-28 | 2023-11-23 | 경북대학교 산학협력단 | 아시네토박터 바우마니에 대한 사멸능을 가지는 박테리오파지 및 이를 포함하는 조성물 |
| CN116514935B (zh) * | 2021-03-04 | 2024-04-30 | 西部(重庆)科学城种质创制大科学中心 | RNA编辑系统的抑制剂AcrIIIA1IPLA35及其应用 |
| WO2023113396A1 (ko) * | 2021-12-14 | 2023-06-22 | 경북대학교 산학협력단 | 클로스트리듐 디피실 세균을 효과적으로 사멸시키는 재조합 항균 단백질의 용도 |
| CN114703173B (zh) * | 2022-03-18 | 2023-06-06 | 福建省农业科学院农业质量标准与检测技术研究所 | 一种λ噬菌体DNA提取试剂盒及提取方法 |
| CN114807106B (zh) * | 2022-04-25 | 2023-09-01 | 昆明市延安医院 | 一种裂解酶pEf51和穿孔素蛋白pEf191的应用 |
| WO2024115430A1 (en) * | 2022-11-28 | 2024-06-06 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Acinetobacter baumannii phages |
| WO2024238999A2 (en) * | 2023-05-17 | 2024-11-21 | The Regents Of The University Of California | Phage therapy for alcohol-associated hepatitis |
| CN118109445A (zh) * | 2024-03-22 | 2024-05-31 | 广西中医药大学 | 一种耐甲氧西林金黄色葡萄球菌噬菌体裂解酶LysLP-122及其制备方法和应用 |
| DE102024113842A1 (de) | 2024-05-16 | 2025-11-20 | bifa Umweltinstitut GmbH | Verfahren zur Verringerung der bakteriellen Last auf bzw. in einer Klimaanlage |
| CN119162119B (zh) * | 2024-07-09 | 2025-09-05 | 深圳先进技术研究院 | Kl2型鲍曼不动杆菌噬菌体及其筛选方法、噬菌体组合物及应用与药物 |
| CN118787727B (zh) * | 2024-08-26 | 2025-03-11 | 中国科学院南海海洋研究所 | 一种清除铜绿假单胞菌的多肽及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| GB9712663D0 (en) * | 1997-06-16 | 1997-08-20 | Borealis As | Process |
| US20060292135A1 (en) * | 1997-10-31 | 2006-12-28 | Lawrence Loomis | Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| AU4971900A (en) * | 1999-05-13 | 2000-12-05 | Exponential Biotherapies, Inc. | Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium |
| AU2001249050A1 (en) | 2000-01-11 | 2001-07-24 | Intralytix, Inc. | Reduction in bacterial colonization by administering bacteriophage compositions |
| RU2186574C1 (ru) * | 2001-01-24 | 2002-08-10 | Яфаев Рауэль Хасанянович | Препарат поливалентного бактериофага против синегнойной палочки, штаммы бактериофага bacteriophagum pseudomonas aeruginosa спбгма им. и.и. мечникова №05, №03, №06 и №07, используемые при приготовлении поливалентного препарата против синегнойной палочки |
| DK1504088T3 (da) * | 2002-03-25 | 2007-12-17 | Univ Warwick | Bakteriofager egnede til behandling og forebyggelse af bakterielle infektioner |
| US7588929B2 (en) * | 2002-12-09 | 2009-09-15 | Phage Biopharm Llc | Production of bacteriophage compositions for use in phage therapy |
| CN101003793A (zh) * | 2007-01-11 | 2007-07-25 | 中国人民解放军第三军医大学 | 噬菌体对环境中致病菌的净化技术 |
| PL215522B1 (pl) | 2008-09-29 | 2013-12-31 | Inst Immunologii I Terapii Doswiadczalnej Pan | Nowe szczepy bakteriofagów do leczenia zakazen bakteryjnych, zwlaszcza szczepami bakterii lekoopornych rodzaju Enterococcus |
| JP5732397B2 (ja) * | 2008-10-10 | 2015-06-10 | ルソメディカメンタ, エス.エー.Lusomedicamenta, S.A. | 抗菌性ファージペプチド及びその使用法 |
| KR20100093626A (ko) | 2009-02-17 | 2010-08-26 | 서강대학교산학협력단 | 슈도모나스 애루지노사에 대한 파아지 치료 |
| PT104837A (pt) | 2009-11-24 | 2011-05-24 | Technophage Investiga O E Desenvolvimento Em Biotecnologia S A | P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o |
-
2010
- 2010-02-05 ES ES16172292T patent/ES2761835T3/es active Active
- 2010-02-05 PT PT161722921T patent/PT3115054T/pt unknown
- 2010-02-05 EP EP16172292.1A patent/EP3115054B1/en active Active
- 2010-02-05 SG SG10201602330VA patent/SG10201602330VA/en unknown
- 2010-02-05 EP EP19201853.9A patent/EP3650034B1/en active Active
- 2010-02-05 EP EP10708834.6A patent/EP2393502B1/en not_active Not-in-force
- 2010-02-05 US US13/148,009 patent/US9134312B2/en active Active
- 2010-02-05 CN CN201510433894.8A patent/CN105456300B/zh active Active
- 2010-02-05 SG SG2011056124A patent/SG173533A1/en unknown
- 2010-02-05 SG SG2014012611A patent/SG2014012611A/en unknown
- 2010-02-05 AU AU2010211456A patent/AU2010211456B2/en active Active
- 2010-02-05 BR BRPI1008663A patent/BRPI1008663B8/pt active IP Right Grant
- 2010-02-05 RU RU2011134315A patent/RU2580248C9/ru active
- 2010-02-05 CN CN201080011689.8A patent/CN102348460B/zh not_active Expired - Fee Related
- 2010-02-05 ES ES19201853T patent/ES2963904T3/es active Active
- 2010-02-05 CA CA2751641A patent/CA2751641C/en active Active
- 2010-02-05 WO PCT/PT2010/000003 patent/WO2010090542A2/en not_active Ceased
- 2010-02-05 PL PL19201853.9T patent/PL3650034T3/pl unknown
- 2010-02-05 CA CA3019013A patent/CA3019013C/en active Active
- 2010-02-05 JP JP2011549110A patent/JP5701777B2/ja active Active
-
2014
- 2014-07-09 RU RU2014127987A patent/RU2671110C2/ru active
-
2015
- 2015-02-18 JP JP2015029248A patent/JP6177264B2/ja active Active
- 2015-09-11 US US14/852,112 patent/US9682110B2/en active Active
-
2017
- 2017-04-20 JP JP2017083578A patent/JP6355792B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012517225A5 (enExample) | ||
| RU2014127987A (ru) | Бактериофаги, белки бактериофагов и способы их применения | |
| JP2013541333A5 (enExample) | ||
| Hirsch et al. | Enhanced susceptibility to infections in a diabetic wound healing model | |
| Serra et al. | Chronic wound infections: the role of Pseudomonas aeruginosa and Staphylococcus aureus | |
| Madhusudhan | Efficacy of 1% acetic acid in the treatment of chronic wounds infected with Pseudomonas aeruginosa: prospective randomised controlled clinical trial | |
| RU2654596C2 (ru) | Композиции коктейля, содержащие антибактериальные фаги, и способы их применения | |
| Birnbach et al. | Comparison of povidone iodine and DuraPrep, an iodophor-in-isopropyl alcohol solution, for skin disinfection prior to epidural catheter insertion in parturients | |
| RU2017106290A (ru) | Бактериофаги, фаговые пептиды и способы их применения | |
| US12280080B2 (en) | Antibacterial composition and uses thereof | |
| JP2017507913A (ja) | E.coli感染のファージを用いての治療 | |
| El-Gayar et al. | Antivirulence and wound healing effects of royal jelly and garlic extract for the control of MRSA skin infections | |
| Suleman et al. | Biofilm-infected pressure ulcers: current knowledge and emerging treatment strategies | |
| Kamel et al. | Characterization of bee venom and its synergistic effect combating antibiotic resistance of Pseudomonas aeruginosa | |
| US20150126571A1 (en) | Method of destroying and preventing bacterial and fungal biofilm by amino acid infusion | |
| Maslow et al. | Concurrent outbreak of multidrug-resistant and susceptible subclones of Acinetobacter baumannii affecting different wards of a single hospital | |
| Gürgen | Excess use of antibiotics in patients with non-healing ulcers. | |
| Al-Awadi et al. | Antibacterial and therapeutic effects of vancomycin-resistant Staphylococcus aureus bacteriocin (VRSAcin) in the treatment of VRSA skin infection in mice. | |
| CN105963680A (zh) | 用于抑制/瓦解生物被膜的抑制剂及其应用 | |
| Hashim et al. | Assessment of Saccharomyces boulardii effect on rats Staphylococcus aureus induced skin infection: an in-vivo study | |
| CN117138024B (zh) | 一种万古霉素-抗菌肽偶合物及其应用 | |
| US11202806B2 (en) | Amoeba therapeutic dressings, biomaterials, and solutions | |
| Kolawole et al. | Wound infections in two health institutions in Ile-Ife, Nigeria: results of a cohort study | |
| Lawrence | Wound infection | |
| Bhende et al. | In vitro antimicrobial effectiveness of 5 catheter insertion-site dressings |